The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy
Stroke is the second-leading cause of death and the third-leading cause of disability worldwide
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
The study evaluated asundexian (50 mg), a once-daily oral anticoagulant candidate, versus placebo—both given alongside standard antiplatelet therapy
India continues to face a major maternal nutrition challenge, with nearly 60% of women affected by anaemia and more than 70% experiencing calcium deficiency
Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina
Call it a major breakthrough for diagnostic imaging
The system also introduces Imaging Scanner Interface 2 (ISI2) capability, enabling direct communication between injector and scanner to improve exam coordination and operational efficiency
Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year
These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke
Subscribe To Our Newsletter & Stay Updated
